tetano
Editor, Senior Moderator
J Clin Med
. 2021 Nov 22;10(22):5458.
doi: 10.3390/jcm10225458.
Pregnancy as a Risk Factor of Severe COVID-19
Aleksander Celewicz[SUP] 1 [/SUP], Marta Celewicz[SUP] 1 [/SUP], Michał Michalczyk[SUP] 1 [/SUP], Paula Woźniakowska-Gondek[SUP] 1 [/SUP], Kamila Krejczy[SUP] 1 [/SUP], Marcin Misiek[SUP] 2 [/SUP], Rafał Rzepka[SUP] 1 [/SUP]
Affiliations
Abstract
Since first being identified in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an etiological agent behind Coronavirus disease 19 (COVID-19), has caused three waves of a global pandemic, with a fourth in progress. Despite its high percentage of asymptomatic and low-symptomatic courses of illness, the SARS-CoV-2 pandemic has claimed a higher death toll than the SARS-CoV and MERS-CoV epidemics because of its high infectivity when compared to the other coronaviruses. High COVID-19 mortality is associated with age and other coexisting morbidities, as well as healthcare quality. According to several studies, pregnant women are at a higher risk of severe COVID-19 infection and adverse pregnancy outcomes (caesarean delivery, pre-term birth, low birth weight, preeclampsia, ICU admission, and need for mechanical ventilation). In our review of recent literature, we focused on the effects of COVID-19 in pregnant women, emphasizing the subcellular pathophysiology of SARS-CoV-2. In this paper, we concentrate on the pathophysiology of sub-cellular changes in COVID-19 and endeavor to highlight the aspects that manifest in physiological pregnancy and potentially create a higher risk of SARS-CoV-2 infection and acute COVID-19 symptoms. Understanding how pregnancy-associated changes can cause a synergistic effect with COVID-19 may point us in the right direction for future prophylaxis and treatment for women undergoing COVID-19 during pregnancy.
Keywords: COVID-19; SAR-CoV-2; pregnancy; vaccine.
. 2021 Nov 22;10(22):5458.
doi: 10.3390/jcm10225458.
Pregnancy as a Risk Factor of Severe COVID-19
Aleksander Celewicz[SUP] 1 [/SUP], Marta Celewicz[SUP] 1 [/SUP], Michał Michalczyk[SUP] 1 [/SUP], Paula Woźniakowska-Gondek[SUP] 1 [/SUP], Kamila Krejczy[SUP] 1 [/SUP], Marcin Misiek[SUP] 2 [/SUP], Rafał Rzepka[SUP] 1 [/SUP]
Affiliations
- PMID: 34830740
- DOI: 10.3390/jcm10225458
Abstract
Since first being identified in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an etiological agent behind Coronavirus disease 19 (COVID-19), has caused three waves of a global pandemic, with a fourth in progress. Despite its high percentage of asymptomatic and low-symptomatic courses of illness, the SARS-CoV-2 pandemic has claimed a higher death toll than the SARS-CoV and MERS-CoV epidemics because of its high infectivity when compared to the other coronaviruses. High COVID-19 mortality is associated with age and other coexisting morbidities, as well as healthcare quality. According to several studies, pregnant women are at a higher risk of severe COVID-19 infection and adverse pregnancy outcomes (caesarean delivery, pre-term birth, low birth weight, preeclampsia, ICU admission, and need for mechanical ventilation). In our review of recent literature, we focused on the effects of COVID-19 in pregnant women, emphasizing the subcellular pathophysiology of SARS-CoV-2. In this paper, we concentrate on the pathophysiology of sub-cellular changes in COVID-19 and endeavor to highlight the aspects that manifest in physiological pregnancy and potentially create a higher risk of SARS-CoV-2 infection and acute COVID-19 symptoms. Understanding how pregnancy-associated changes can cause a synergistic effect with COVID-19 may point us in the right direction for future prophylaxis and treatment for women undergoing COVID-19 during pregnancy.
Keywords: COVID-19; SAR-CoV-2; pregnancy; vaccine.